Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (June 2024)
19 slides from Chimeric Therapeutics's shareholder meeting presentation, Jun 11, 2024
Slide 1: Extraordinary General Meeting Corporate Overview
For personal use only ASX:CHM Extraordinary General Meeting Corporate Overview 11 June 2024
Slide 2: Disclaimer
DISCLAIMER For personal use only Certain statements contained in this presentation, including, information or studies to be completed or provided prior to their without limitation, statements containing the words “believes,” approval of our products. “plans,” “expects,” “anticipates,” and words of s
Slide 3: Investor Highlights
INVESTOR HIGHLIGHTS For personal use only Innovative Pipeline CORPORATE PROFILE 3 Novel Cell Therapy Technologies Exchange ASX: CHM Early Clinical Promise Share Price $0.018 4 Phase 1 clinical trials open and enrolling (6 June 2024) 30+ Patients treated 52 Week Range $0.018- 0.047 Near Term Clinical
Slide 4: Chimeric's Broad Portfolio
CHIMERIC’S BROAD PORTFOLIO 3 Novel cell therapies; 4 Clinical Trials CHM CDH17 CHM CLTX CHM CORE-NK For personal use only CAR-T CAR-T “Off the shelf” NK Technology from: Technology Technology from:from: Technology from: Phase 1a Completed City of Hope Phase 1/2 Trial Open Phase 1b Trial Open Phase 1
Slide 5: CHM CDH17 CAR-T Trial Open
CHIMERIC: CHM CDH17 CAR-T Trial Open PERSONALISED CAR-T: Autologous CHM CDH17 For personal use only CAR-T First in class CDH17 CAR T for Technology from: gastrointestinal cancers FDA IND clearance Nov 23 Phase 1/2 Trial Open in Colorectal Cancer, Gastric Cancer and Neuroendocrine Phase 1/2 Trial Ope
Slide 6: CHM CDH17 Pre-Clinical Efficacy
CHM CDH17 Pre-Clinical Efficacy CHM CDH17 CDH17 CAR T induced complete eradication of tumours with no only CHM 2101 relapse in seven mouse models For personal use Neuroendocrine Gastric Pancreatic Tumours Cancer Cancer Source: Feng et al., Nature Cancer, 2022 6
Slide 7: CHM CLTX CAR-T
CHIMERIC THERAPEUTICS: CHM CLTX CAR-T PERSONALISED CAR-T: Autologous CHM CLTX For personal use only CAR-T Technology from: First in class CLTX CAR T for brain cancer and solid tumours Preliminary Positive Phase 1A Clinical Trial in Relapse/ Recurrent Glioblastoma Phase 1a Completed City of Hope Ongo
Slide 8: CHM CORE-NK
CHIMERIC: CHM CORE-NK Off the shelf: Allogeneic CHM CORE-NK For personal use only “Off the shelf” NK NK cell expansion platform Universal Donor Technology from: Positive Phase 1A Clinical Trial in Colorectal Cancer and AML Two ongoing Phase 1B Clinical Trials in AML and CRC AML: Cohort 1 cleared, mo
Slide 9: Key Clinical Catalysts
KEY CLINICAL CATALYSTS Delivering in 2023 and Advancing Key Clinical Milestones in 2024 2023 Achievements 2024 Milestones For personal use only FDA IND Clearance for Ph. 1/2 Trial in Ph. 1/2 Site Initiation CHM CDH17 Colorectal Cancer, Gastric Cancer and • Ph. 1/2 1st Patient Treated CHM 2101 Ne
Slide 10: For More Information
FOR MORE INFORMATION For personal use only www.chimerictherapeutics.com www.linkedin.com/company/chi meric-therapeutics/ @chimeric9352 Dr Rebecca McQualter Chief Operating Officer Chimeric Therapeutics Ltd Melbourne Australia T: +61498966180 investor@chimerictherapeutics.com 10
Slide 11: Appendix
For personal use only APPENDIX
Slide 12: Chimeric Leadership Team
CHIMERIC LEADERSHIP TEAM EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION EXPERIENCE EXPERTISE PROVEN For personal use only 75+ Years of Cell Therapy Experience 50+ Development Programs 5/6 FDA-Approved CAR T Cell Therapies Dr Rebecca McQualter Dr Eliot Dr Jason Dr Stephanie Kelly Chief Opera
Slide 13: Chimeric: Positioned for Success
CHIMERIC: POSITIONED FOR SUCCESS Phase 1 2024 Current Progress Neuroendocrine Tumours For personal use only CHM CDH17 Gastric Cancer Personalised Autologous CHM 2101 Medicine Colorectal Cancer Recurrent/ Progressive Glioblastoma COH Phase 1A CHM CLTX Recurrent/ Progressive Glioblastoma CHM Phase 1B
Slide 14: CHM CDH17 CAR T Phase 1/2 Clinical Trial in GI Cancers
CHM CDH17 CAR T PHASE 1/2 CLINICAL TRIAL IN GI CANCERS CHM CDH17 only CHM 2101 OBJECTIVE: Characterize the safety and Colorectal Cancer For personal use tolerability of CDH17 CAR and determine the recommended 450 X 106 CLINICAL TRIAL AMENDMENTS Phase 2 dose (RP2D) for Phase 2 NETs Tumor Tumor Specif
Slide 15: Positive Preliminary Phase 1A Clinical Data in Recurrent Glioblastoma
POSITIVE PRELIMINARY PHASE 1A CLINICAL DATA IN RECURRENT/ PROGRESSIVE GLIOBLASTOMA CLTX CHMonly DISEASE SURVIVAL SAFETY CHM 1101 CONTROL RATE For personal use ~10 months Generally, well tolerated 55% Median survival in patients that achieved disease No Dose Limiting Toxicities 14+ months control Dis
Slide 16: CHM CLTX CAR: Advancing Development to Multi-Site Phase 1B
CHM CLTX CAR ADVANCING DEVELOPMENT TO MULTI-SITE PHASE 1B CLTX CHMonly CHM 1101 OBJECTIVES: • PFS, OS, ORR PART A PART B For personal use • Safety & Feasibility DOSE CONFIRMATION DOSE EXPANSION • RP2D SAFETY & EFFICACY ASSESMENT • Cellular Kinetics PATIENT POPULATION: 440 X 440 X PHASE 2 • Recurrent
Slide 17: CHM CORE-NK Development Plan
CHM CORE-NK DEVELOPMENT PLAN OPTIMIZING FOR THE FUTURE useCORE-NK only CHM 0201 Combinations 1. Exploring novel combinations utilizing NK cells with standard of care therapies For personalCHM 2. CHM 0301 Next Generation Platform Core NK Next generation armored platform development 3. CAR-NK Products
Slide 18: ADVENT-AML Phase 1B Clinical Trial
ADVENT-AML PHASE 1B CLINICAL TRIAL CHM CORE-NK 0201 + AZA + VEN IN FRONT-LINE AML HIGH UNMET NEED IN AML useCORE-NK only Despite treatment advances, outcomes for AML patients not eligible for intensive chemotherapy or allogeneic stem cell transplant are poor CHM CORE-NK 0201 + AZACITIDINE + VENETOCL
Slide 19: CHM CORE-NK 0201 + Vactosertib Re-Opened
CHM CORE-NK 0201 + Vactosertib Re-Opened FDA APPROVED FIRST EVER TRIAL OF NK CELLS WITH VACTOSERTIB useCORE-NK only A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGF-beta Receptor I Inhibitor Vactosertib For personalCHM
Chimeric Therapeutics — Shareholder Meeting (June 2024) on 6ix